Although the cytoprotective effects of glutathione (GSH) are well established, additional roles for GSH in brain function are being identified that provide a pharmacological basis for the relationship between alterations in GSH homeostasis and the development of certain neurodegenerative processes. Thus, GSH and glutathione disulfide (GSSG) appear to play important functional roles in the central nervous system (CNS). A symposium, focussing on the emerging science of the roles of GSH in the brain, was held at the 37th annual meeting of the Society of Toxicology, with the emphasis on the role of glutathione in neuroprotection and neurotoxicity. Jean Francois Ghersi-Egea opened the symposium by describing the advances in our understanding of the role of the blood-brain and blood-cerebral spinal fluid (CSF) barriers in either limiting or facilitating the access of xenobiotics into the brain. Once within the brain, a multitude of factors will determine whether a chemical causes toxicity and at which sites such toxicity will occur. In this respect, it is becoming increasingly clear that GSH and its various conjugation enzymes are not evenly distributed throughout the brain. Martin Philbert discussed how this regional heterogeneity might provide a potential basis for the theory of differential sensitivity to neurotoxicants, in various regions of the brain. For certain chemicals, GSH provides neuroprotection, and Edward Lock discussed the selective toxicity of 2-chloropropionic acid (CPA) to the cerebellum and how its modification by modulating brain thiol status provides an example of GSH acting in neuroprotection. The sensitivity of the cerebellum to CPA may also be linked to the ability of this compound to activate a sub-type of the NMDA receptor. Thus, GSH and cysteine alone, or perhaps as conjugates with xenobiotics, may play a role in excitotoxicity via NMDA receptor activation. In contrast, certain chemicals may be converted to neurotoxicants following conjugation with GSH, and Arthur Cooper described how the pyridoxal 5-phosphate-dependent, cysteine conjugate ␤-lyases might predispose the brain to chemical injury in a GSH-dependent manner. The theme of GSH as a potential mediator of chemicalinduced neurotoxicity was extended by Terrence Monks, who presented evidence for a role for GSH conjugation in (؎)-3,4-methylenedioxyamphetamine-mediated serotonergic neurotoxicity.
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Roles of Blood-Brain Interfaces in Regulating Drug Influx into the Brain and Conjugate Elimination from the Central Nervous System
Exposure of the brain to drugs and neurotoxicants occurs mainly via the general circulation. This exposure is modulated by: (1) the specific morphological and biochemical properties of the structures that form the blood-brain interfaces, and (2) detoxication pathways that function both at the blood-brain interfaces and within the brain parenchyma. The capillaries of the cerebral parenchyma form the main interface between the blood circulation and the brain, the blood-brain barrier (BBB). These cells lie on a basal membrane that also engulfs pericytes, and the cells are almost completely surrounded by astrocytic processes. The ability of these cells to prevent the entry of a number of compounds into the brain arises from their intercellular junctions, which are tight (zonulae occludens type) and prevent the paracellular passage of solutes into the brain. Therefore, brain entry across the BBB occurs only by the transcellular pathway, either by passive diffusion or via specific transporters. Such transport systems exist for hydrophilic nutrients such as glucose or amino acids that cannot dissolve in the lipid membranes, (Fenstermacher, 1989; Schlosshauer, 1993) . Therefore, the BBB should be viewed as an interface, actively regulating exchange processes between blood and brain tissue. Among brain structures, only the circumventricular organs. (CVOs) lack a typical BBB. These seven small brain areas, located near a cerebrospinal fluid (CSF) compartment, are involved in neuroendocrine regulation. With the exception of the subcomissural organ, the CVOs have fenestrated capillaries that generally lack tight junctions, and are surrounded by large perivascular spaces (Gross and Weindl, 1987) .
The CSF is secreted in large part by the choroid plexuses into brain ventricles. CSF circulates within the interconnected lateral, third and fourth ventricles and into the subarachnoid spaces that surround the whole brain, before draining into the venous blood through the arachnoid granulations, and into the cervical lymph nodes. The cells that form the interface between the CSF and the cerebral parenchyma, (the ependyma in the ventricles, the glia limitans in the subarachnoid spaces) are not sealed by tight junctions. Thus the CSF should be considered as part of the central nervous system (Davson and Segal, 1996, Ghersi-Egea et al., 1996) . This fluid is separated from the blood compartment upstream by the choroid plexus (the blood-CSF barrier [BCSFB] ), and downstream by the pia-arachnoid membranes. The choroid plexus is composed of an outer choroidal epithelium protruding into a ventricle, and an inner connective tissue stroma containing sinusoidal, fenestrated capillaries. In the choroid plexus, the effective barrier between the blood and the brain compartment (CSF) is localized at the choroidal epithelium, whose cells are joined by tight junctions. This epithelium, in addition to CSF secretion from blood, has several functions, such as nutrient and electrolyte transport, clearance of toxic neurotransmitter metabolites, and hormonal regulation (Davson and Segal, 1996) .
Factors regulating brain influx of xenobiotics.
To reach the central nervous system, drugs or neurotoxicants have to cross either the luminal and antiluminal membranes of the endothelial cells, or the basolateral and apical membranes of the choroidal cells. Thus the extent of their influx into the parenchyma will be dependent on their ability to dissolve and diffuse through these cells, which is mainly a function of their liposolubility and their size (Fenstermacher, 1989) . Exceptions include the CVOs (which as noted above lack capillary tight junctions) and the brain at early developmental stages when the BBB junctional complexes are not entirely formed (Gross and Weindl, 1987, Stonestreet et al., 1996) . Influx at the BBB and BCSFB will also be modulated by the capacity of the drug to bind to circulating proteins or red blood cells, and by the characteristics of the microcirculation, i.e., the rate of cerebral blood flow and the capillary surface area available for exchange. The last two parameters contribute to differences in brain uptake observed among different cerebral regions (Fenstermacher, 1989) . The involvement of transport proteins and the metabolic capacity of the capillaries and choroid plexuses toward xenobiotics represent additional specific mechanisms influencing the influx of xenobiotics into the brain.
Transport proteins can either facilitate or reduce the entry of a drug into the brain compartment. At the BBB, the brain influx of the anticancer drugs melfalan and acivicin is facilitated by the large neutral amino acid transporter (Chikhale et al., 1995; Takada et al., 1991) . P-glycoprotein, a multidrug-resistanceassociated protein is responsible for the efflux of vinca alkaloids and other anticancer drugs from the BBB endothelial cell back into the blood. This leads to a very low net influx of the drug into the brain (reviewed in Tsuji and Tamai, 1997) . It is likely that other transport proteins are also involved in drug exchange at the BBB. For example, ␤-lactam antibiotics such as cefodizime enter the brain by a specific mechanism at the BBB (Suzuki et al., 1997) . Specific efflux mechanisms at the BBB, which are usually at least partly saturable and probenecid sensitive, have been reported for drugs such as azidothymidine, baclofen, and cefodizime. Thus, for some compounds, the net influx from blood to the brain will be a function of the relative rates of specific transport in both directions. The transport proteins responsible for these specific influx and efflux pathways at the BBB remain to be identified.
A rapid, specific efflux from CSF at the choroid plexus has also been demonstrated for different compounds, such as benzylpenicillin, quinolones, cimetidine, and anionic pesticides such as 2,4-dichlorophenoxyacetic acid and 2,4,5-trichlorophenoxyacetic acid (Suzuki et al., 1997 ). An organic anion transport protein, localized at the apical (CSF facing) membrane of the choroidal epithelium (Angeletti et al., 1997) , is likely to be involved in the efflux of several of these compounds. These examples illustrate how the concentration of a given compound in the extracellular spaces of brain parenchyma and in the CSF is determined by several parameters. These include: (1) time course of the free drug concentration in the plasma, (2) the rates of passive or transporter-mediated influx at both BBB and BCSFB, (3) the rates of passive or transporter-mediated efflux at the blood-brain interfaces, and (4) the movement of the drug within and between the parenchyma and the CSF.
The cerebral capillaries and the choroid plexuses contain several enzymes that act as metabolic barriers toward endogenous neurotransmitters and their precursors (Hardebo and Owman, 1980) . Similarly, the hypothesis that the biotransformation of a drug may influence its brain penetration has arisen from the discovery of drug-metabolizing enzymes in both the cerebral capillaries and the choroid plexuses forming the blood-brain interfaces (reviewed in Ghersi-Egea et al., 1995; Strazielle and Ghersi-Egea, 1998) . Specifically, the high activities recorded for some of these enzymes in the choroid plexus suggest that this tissue is a major site for drug metabolism in the brain. These choroidal enzymes may metabolize bloodborne substrates, but also act as "liver-like" detoxication systems for the brain and CSF (Ghersi-Egea et al., 1994) . The choroid plexus differentiates early during development, and several drug-metabolizing enzymes are already expressed at a high level in the organ in newborn animals (Strazielle and Ghersi-Egea, 1997) . The 3 different choroid plexuses that exist in the brain may not perform identical functions, as they are located in different compartments of the ventricular system. Material released in the CSF from the 2 choroid plexuses located in the lateral ventricles can readily exchange with the periventricular cerebral structures across the ependyma while flowing downstream. By contrast, most of the choroid plexus from the third ventricle lies in the pineal recess, which is surrounded by a pouch of subarachnoid space (the velum interpositum). Most of the choroid plexus from the 4th ventricle lies in the lateral recesses of this ventricle, which are separated from the surrounding neuropil by a thick multilayered glia limitans, limiting exchanges between CSF and the parenchyma (Ghersi-Egea et al., 1996) . In addition to their localization, the choroid plexuses differ in their morphology and their vascularization. Thus, the capillaries of the 4th ventricle choroid plexuses, arranged in short loops, are more closely covered with the choroidal epithelium than the more regular and parallel arrangement of capillaries in the lateral ventricle choroid plexuses (Gomez and Potts, 1981) . The choroid plexuses also differ in their metabolic properties and enzymatic contents, as shown for the membrane-bound epoxide hydrolase, whose activity is several-fold higher in the lateral ventricle choroid plexuses than in other choroidal tissue. (Strazielle and Ghersi-Egea, 1997) . How these differences in physiology translate to differences in xenobiotic biotransformation capacity awaits further evaluation Blood-brain interfaces can efficiently prevent the blood-tobrain passage of some xenobiotics by metabolic processes. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces a Parkinson-like syndrome after biotransformation into its dihydropyridinium form by monoamine oxidase-B (MAO-B). However, when MPTP is metabolized by MAO-B at the BBB, its subsequent entry into the brain is impaired. Thus, species such as rodents, whose cerebral capillaries have high levels of MAO-B, are protected from MPTP neurotoxicity, whereas primates and humans, having low levels of endothelial MAO-B, are more sensitive to MPTP toxicity (Riachi et al., 1988) . Another example relates to the large increase in the brain uptake of 5-(glutathion-S-yl)-␣-methyldopamine, a metabolite of 3,4-(Ϯ)-methylenedioxyamphetamine (MDA), when ␥-glutamyl transpeptidase (␥-GT) is inhibited by acivicin (see below). This shows that ␥-GT efficiently metabolizes the blood-borne GSH conjugate at the BBB, thus limiting its entry into the brain (Miller et al., 1996) .
Pathways of conjugate elimination from the brain. The cells forming the neuropil can also metabolize drugs or toxicants that have the capacity to enter the brain parenchyma. This ability may vary among different cerebral structures and among cell types, and may result in either detoxication or bioactivation (Teissier et al., 1998; and below) . The elimination of drug metabolites from the brain, and specifically of conjugates, is complicated by their hydrophilic nature, which limits their passive elimination into blood through the BBB. Three routes of elimination, however, can be discerned. First, the metabolite can cross the BBB back into the blood. As passive diffusion is expected to be slow for polar metabolites, this route may be more significant if a transporter is involved. Evidence for such a mechanism occurring at the BBB includes:
(1) the in vivo demonstration that 1-naphthyl-␤-D-glucuronide injected in the rat cortex is eliminated into the blood by a partially saturable mechanism (Leininger et al., 1991) , and (2) the measurement of a specific uptake of dinitrophenyl-GSH in vitro into inside-out membrane vesicles of an endothelial brain cell line (Homma et al., 1999) . The possible further metabolism of GSH conjugates within the brain by the mercapturic acid pathway, prior to elimination in the blood, will be discussed later in this review.
The efflux of a conjugate that reaches the CSF can occur via the choroid plexus. Evidence for the involvement of specific transport systems exists. For example, estradiol 17-␤-D-glucuronide is rapidly cleared, in vivo, from the CSF, and is actively concentrated by isolated choroid plexus. This process probably involves the organic anion transport protein (Kusuhara et al., 1998) . In view of growing evidence of the multiple roles of choroid plexuses in brain protection and brain homeostasis, it is likely that other transport proteins are involved in efflux processes at the BCSFB. Specifically, because the activities of enzymes responsible for phase I (functionalization) and phase II (conjugation) drug metabolism are relatively high in the choroid plexus (Ghersi-Egea et al., 1995) , transporter proteins responsible for the cellular efflux of drug metabolites (phase III of drug metabolism process; Ishikawa, 1992) require further attention.
The ability of CSF to act as a sink constitutes a non-specific pathway for the brain to dispose of polar compounds. Secreted by the choroid plexuses, the CSF circulates from the ventricles into the subarachnoid spaces from where it is reabsorbed either into the venous blood or into the lymphatics by a bulk flow process. Metabolites and other polar compounds synthesized by brain cells can either diffuse out of the tissue into the ventricular CSF, or perhaps drain along the parenchymal and subdural perivascular spaces into the subarachnoid space (Davson and Segal, 1996) . Here they can then be removed from the CNS with the bulk flow of CSF. It is important, however, to emphasize that the circulation of CSF and the exchange processes between the cerebral parenchyma and the CSF are more complex than previously thought. With respect to the latter, in most areas simple diffusion occurs at the ependymal level between the brain parenchyma and the ventricular CSF. This exchange process, is however, prevented between both ventricular and subarachnoidal CSF and the CVOs. These exchanges are also strongly limited between the subarachnoid spaces and the midbrain structures, which are bordered by a thick, multilayered glia limitans (Ghersi-Egea et al., 1996) .
These specific anatomic and physiologic properties of CSF/ brain interfaces influence the actual concentration of a xenobiotic or its metabolites in a specific brain structure. Once a chemical has successfully gained access to the brain, a variety of factors will determine whether or not the chemical produces toxicity. These factors include, but are not limited to, the distribution of enzymes capable of metabolizing chemicals to toxic metabolites, the presence or absence of specific cellular targets (uptake carriers, receptors, etc), and the distribution and efficiency of cellular protection mechanisms.
Cellular Substrates for Differential Sensitivity to Neurotoxicants
The ability of the mammalian nervous system to integrate and control sensory input and effector organ responses, is predicated on intrinsic cellular and physiological heterogeneity. Neural tissues are heterogeneous with respect to regional cellular composition, neurotransmitters, receptors, function, and susceptibility to and recovery from attack by chemicals in the diet and environment. Specific cells in distinct anatomical regions of the brain may be vulnerable to chemical injury due to the expression of receptor proteins and enzymes that permit entry and activation of neurotoxic intermediates. Cells situated at the interface with CSF or blood, and the internal or exterior surfaces of the brain, display parallel specialization in xenobiotic metabolism, presumably as a biochemical adjunct to the physical barriers (see above). However, once a neurotoxicant gains access to the brain, it encounters a plethora of targets. Since many of the common targets of chemicals are found in cells that are not affected by the neurotoxicant, models that invoke local bioactivation or detoxication of the xenobiotic have recently gained favor.
Regional cellular responses to neurotoxicants. Of those neurotoxic chemicals that gain access to the parenchyma of the brain, many require metabolic modification for pharmacologic efficacy, toxicity, or elimination. Conjugation with GSH is a major phase II metabolic pathway in the brain. However, neither GSH nor the various isoforms of GSH S-transferase (GST) are equally distributed between the component cells of the nervous system (Cooper, 1997; 1998; Shaw, 1998) . Similarly, phase I metabolic enzymes, such as the cytochromes P450, display significant regional and cellular heterogeneity in their distribution Mesnil et al., 1984) . The apparent inability of neural cells to completely metabolize xenobiotics may either confer protection (if the chemical requires activation) or render the cell vulnerable to the deleterious effects of a reactive intermediate. It is increasingly clear that along with considerable physiologic specialization, there is parallel cellular division of metabolic function in neural tissues. The existence of regional cellular differences in metabolic function raises the possibility of metabolically-mediated, cell-specific genetic responses to reactive intermediates produced either in situ or in neighboring cells. Coordinate expression of phase I and II metabolic enzymes may, therefore, be a critical determinant of regional sensitivity to neurotoxicants (Grant and Ironside, 1995) and may provide a theoretical framework for targeted drug delivery to the nervous system.
The principle of astrocytic metabolism of xenobiotics with secondary consequences on neurons is well established. The metabolism of MPTP is such an example. Following activation by astrocytic mitochondrial MAO-B, the pyridinium ion is concentrated in nigral neurons (DiMonte, 1986; Ramsey et al., 1989) . The activated pyridinium ion, MPP ϩ is a potent inhibitor of mitochondrial NAD oxidase (Kindt et al., 1987) . Given that mitochondrial NAD oxidase is ubiquitous, it is important to note that astrocyte mitochondria are largely spared. The differential toxic effect of MPP ϩ further establishes the concept of differential susceptibility of mitochondria to attack by neurotoxicants in vivo. The resulting lesions are focal, and in the initial stages frequently involve the glia. Perturbation of metabolic regeneration of reducing equivalents with resulting decreased regeneration of GSH and increased oxidative stress provides a common link between the mechanism of action of these chemically disparate species. Nevertheless, precise relationships between disruptions in redox homeostasis and regional cellular energy metabolism need to be further elucidated. (Meister and Anderson, 1983) . These normal cellular processes include amino acid transport and detoxication of xenobiotics Rickert, 1985,1987; Halliwell and Gutteridge, 1989) . GSH also protects against pro-oxidant damage due to ischemiareperfusion (Kinuta et al., 1989; Kish et al., 1985 Kish et al., ,1986 , and endogenous substrates such as dopamine (Spina and Cohen, 1989) . Thus, the cellular segregation of GSH content in the central nervous system raises the important question of how deficient cells are protected from the plethora of endogenous and exogenous oxidative insults to which they are continually exposed.
Distribution of glutathione, associated enzymes, and their relationship to differential susceptibility. GSH is required for a variety of biosynthetic reactions in mammalian cells
The observation that GSH is unequally distributed between the glia and neurons of the central nervous system markedly changed perceptions of mechanisms of oxidative stress in populations of cells targeted by xenobiotics (see Lowndes et al., 1995 for review) . The neuronal cell body contains low levels of GSH while concentrations in astrocytes, ependyma, oligodendrocytes, and vascular endothelial cells are relatively high Makar et al., 1994; Philbert et al., 1991) . Similarly, the ability of neural tissues to enzymatically conjugate GSH to various substrates is heterogenously distributed by region, cell type and organelle (Abramovitz et al., 1988; Cammer et al., 1989; Johnson et al., 1993; Philbert et al., 1995) . In general, ␣-isoforms of GST are expressed in the nuclei of selected neurons throughout the nervous system. Expression of -and -isoforms are confined to astrocytes and oligodendrocytes, respectively. These data strongly suggest that exposure to lipophilic electrophiles, which are detoxified by GSH-dependent pathways, may show cell-and regionspecific effects based on their affinity for one isoform of GST or another. However, little is known about the ability of such potentially neurotoxic species to selectively deplete GSH per se in specific neural cell populations or their sub-cellular compartments.
Information on the relative cellular distribution of GSH peroxidase in the mammalian brain is limited, and frequently contradictory (Ushijima et al., 1986a,b) . Geremia et al. (1990) report higher activities of GSH reductase and GSH peroxidase in glial-enriched fractions of postnatal rat brain. However, while Savolainen (1978) described glial activities of GSH peroxidase as approximately 10-fold those of neurons, Makar et al. (1994) suggest that the activity of GSH peroxidase in the astrocytes derived from the forebrain of chicks is comparable to neurons in the same region, regardless of age. Data obtained with cultures of astrocytes and cerebellar granule cells from newborn rats indicate that astrocytic GSH peroxidase activity is 3.5-fold higher than the neuronal counterpart (Huang and Philbert, 1995) . Reported differences in glial activities of GSH peroxidase may reflect the species of origin and time in vitro, with a generally consistent trend for higher astrocytic activity, suggesting that the cytoplasm of astrocytes is better able than neurons to metabolize hydrogen peroxide at the expense of GSH. This is a potentially important finding since GSSG is rapidly removed from the cell via active transport mechanisms, further depleting cellular stores of GSH and compromising energy metabolism (Eklow et al., 1984) . How differences in cellular/intracellular localization of GSH peroxidase affects the neurotoxic outcome following oxidative stress is poorly understood.
Potential role of cellular distribution of GSH during development. The morphological and biochemical heterogeneity of embryonal cells, as they develop from common stem cells to differentiated cell types with specific structures and functions, is well characterized. Regulation of changes in differentiation involves complex patterns of gene expression, which receive cues from both endogenous and exogenous origins. The correlation between the status of GSH, related antioxidant enzymes, and radical scavengers and the developmental status of cells may be of critical significance in this area. A "free-radical theory of development" proposes that oxidative signals produced as bursts of reactive oxygen species (ROS) serve as one of many cues for the regulation of cell proliferation and differentiation (Allen and Venkatraj, 1992) . Acquired differences in the capacity of cells to modulate the duration and intensity of the oxidative event are likely to determine the extent of developmental changes that occur. These theories may have important implications for understanding mechanisms of developmental toxicology. Exposure to chemicals capable of altering cellular redox status or of eliciting oxidative stress may modify normal signaling pathways that would deregulate normal development, resulting in anatomical or functional defects.
The role of GSH in the regulation of development is not restricted to its activity as a cytoprotectant, but involves other, probably more important, functions. As the major intracellular thiol in most cell types, GSH is required for maintaining the cellular reducing environment, which is essential for the optimal activity of most enzymes and other components of the cellular machinery (Hiranruengchok and Harris, 1995) . Variations from the normal reducing environment produced through environmental or physiological signals can interfere with cell proliferation and differentiation. Generally, cells with high GSH content are more likely to proliferate, while cells that have lower GSH concentrations are likely to undergo differentiation and cease division (Hamilos et al., 1989; Horton et al., 1997; Outhiriaradjou and Balasubramanian, 1997) .
Epithelial cells of ectodermal origin (such as those found in the neuroectoderm) appear to have significantly less GSH than cells of the underlying mesoderm. Differentiation, manifest as newly acquired structure and function of these cells, conforms to the earlier generalization regarding the loss of GSH in differentiating cells. In addition, heterogeneity is also observed within structures such as the neuroepithelium of the closed neural tube, and in the decidual capsule surrounding the developing conceptus. Selective decreases in GSH levels in the developing nervous system, as a result or cause of differentiation events, may also have implications for the increased potential of this organ to be more sensitive to chemical and environmental insults. The significance of these differences and their direct association with any specific progenitor cell type or function has not yet been established. Also, cellular responses to chemical depletion of GSH appear to be different, both among and within embryonal populations. Sustained punctate staining for GSH suggests that the ability exists in some cell types to maintain high GSH concentrations in selected organelles such as the mitochondria. Current efforts in our laboratories are focused on attempting to correlate GSH and redox status with proliferation and differentiation states in the intact conceptus.
As the nervous system evolves from a laminar embryonal plate to the complex 3-dimensional structure of adulthood, the cellular and regional distribution of GSH and related enzymes undergo marked changes (Harris and Philbert, unpublished observations; Beiswanger et al., 1995) . Whether the relative lack of vulnerability of the laminar structure (i.e., access to the neural parenchyma only at the top and bottom of neural lamina in utero) is mirrored by a diffuse and relatively uniform distribution of GSH and GST is not known. However, as the more complex multilayered and convoluted nervous system becomes infiltrated by the vascular and ventricular systems, the ratio of surface area to parenchymal volume increases by many orders of magnitude. Consequently, the surfaces through which potentially neurotoxic agents might enter the brain are protected, not only by GSH but by a host of enzymes capable of bio-transformation. The second line of defense is represented by the astrocytic ensheathment of blood vessels and neurons. Here, many, but not all of the protective metabolic systems are found in abundance. Neurons are thus able to function (neurotransmission) in a relatively unencumbered manner.
The main function of the neuron is to transmit signals from one part of the body or nervous system to another. In a tissue with such inherent anatomical heterogeneity, this represents the ultimate segregation of physiology and function. Whether or not the cellular and subcellular distribution of GSH and its related enzymes is directly associated with protection from xenobiotic insult remains to be determined. It is clear, however, that data obtained from homogenates of even tiny anatomical structures may give misleading results with regard to protection from or susceptibility to potential neurotoxicants. The picture is further complicated by the fact that phase I and II metabolic enzymes are housed in proximal, but separate, cells. Given the unique metabolic pathways that must be followed by each class of chemical to give rise to the damaging species, it is likely that micro-pharmacokinetics (neuron/astrocyte; astrocyte/endothelial cell; endothelial cell/blood flow) plays a major role in the differential susceptibility of cells within a particular brain region.
The Role of Glutathione in 2-Halopropionic Acid-Induced Cerebellar Toxicity
It should be evident that it is not well understood why selected populations of cells within the nervous system are vulnerable to various chemicals, nor is the role that GSH plays in this type of selective toxicity. As noted above, GSH has a major intracellular role in protecting the brain against oxidative stress, either by interacting directly with ROS or by participating in enzyme-catalyzed redox cycling reactions. For example, glutathione peroxidase catalyses the reduction of potentially toxic H 2 O 2 or lipid peroxides (ROOH) to H 2 O (or ROH) with the concomitant conversion of GSH to glutathione disulfide (GSSG). The presence of a relatively large pool of GSH in the mitochondria also plays a crucial role in protecting this organelle against metabolic insults such as ROS. GSH is also important in detoxifying potentially harmful xenobiotics as discussed earlier. However, with certain chemicals, subsequent metabolism of the derived GSH conjugate can lead to the formation of highly reactive sulfhydryl-containing metabolites that cause cellular injury (Anders and Dekant, 1998) . GSH is also a non-toxic storage form of cysteine, and increases in extracellular concentrations of cysteine/cystine (cysteine is readily oxidized non-enzymatically to cystine in the extracellular space) are excitotoxic (Olney, 1990) , acting as an agonist at the N-methyl-D-aspartate (NMDA) receptor (Fonnum, 1997) . Excess extracellular glutamate is also toxic to neurons, leading to activation of NMDA and other glutaminergic receptors (see below). GSH and GSSG can also act as agonists at the NMDA receptor (Leslie et al., 1992; Ogita et al., 1995) suggesting that xenobiotic-derived GSH-conjugates may also act as agonists. Astrocytes contain transport systems for uptake of amino acids including glutamate, glycine and cysteine, and it has been suggested that synthesis of GSH may be a means of removing or sequestering inside cells potentially toxic glutamate and cysteine (Dringen and Hamprecht, 1996) .
We have used the chemical L-2-chloropropionic acid (L-2-CPA), which produces selective necrosis to granule cells of the rat cerebellum without affecting granule cells in the forebrain, as a tool to explore (1) the role of GSH in the metabolism of this xenobiotic and related 2-halopropionic acids, (2) the putative role of GSH as a neuroprotective agent, and (3) the role of the NMDA receptor in the neurotoxicity to try and understand the basis for the selective toxicity of this chemical to cerebellar granule cells.
Previous studies have shown that 2-chloropropionic acid, which is used as a starting material for the manufacture of a number of chemicals, produces selective damage to the cerebellum when fed to rats (O'Donoghue, 1985) . The cerebellar injury can also be produced by a single dose of either the L-or D-isomers of 2-chloropropionic acid (L-2-CPA and D-2-CPA). Following oral administration of 750 mg/kg, signs of locomotor impairment were seen between 36 and 48 h, which were associated with extensive necrosis of cerebellar granule cells, cerebellar oedema, and at later times, astrogliosis. The Purkinje cells were largely spared (Simpson et al., 1996; Jones et al., 1997) .
Following a neurotoxic dose, L-2-CPA is rapidly absorbed from the gastrointestinal tract into the blood stream, giving a peak plasma concentration within 1 h of about 6 mM. L-2-CPA is then cleared from the plasma with a half-life of 2.6 h . The peak concentration of L-2-CPA in both the cerebellum and forebrain is similar (2.3 mM), occurring 1-2 h after dosing, and is then cleared from the brain more slowly than from the plasma. No marked retention of L-2-CPA or a metabolite was seen in the cerebellum, nor is there any obvious evidence of accumulation in the cerebellum following multiple dosing . The cascade of events leading to excitotoxicity may be triggered at the time of the peak cerebellar L-2-CPA concentration, but may then take time to override the compensatory mechanisms in neuronal cells (e.g., ability to scavenge ROS and sequestration of elevated [Ca 2ϩ ]i) before the necrosis is produced.
The major routes of L-2-CPA metabolism are via GSH conjugation and oxidation to carbon dioxide. This latter route presumably involves the formation of a CoA ester, which is then processed via the tricarboxylic acid cycle in a manner analogous to the metabolism of propionic acid. The major components found in the urine of rats given L-2-CPA are the unchanged parent compound and the mercapturic acid. In plasma, the only metabolite detected is the cysteine conjugate, which persisted for ϳ12 h at a concentration of about 100 M . Consistent with the formation of the mercapturate, both L-2-CPA and D-2-CPA produce a dose-and time-dependant depletion of hepatic non-protein sulphydryl content, mainly GSH. Following a neurotoxic dose, the depletion of GSH in hepatic tissue is rapid, with an 80 -90% reduction at 4 h, and about a 50% reduction at 24 h after dosing; liver GSH returns to normal by 48 h when the rats are showing clinical signs of motor incoordination . In the cerebellum and forebrain, the decrease in nonprotein sulfhydryls is more gradual, reaching its nadir about 24 h after dosing and still not recovering by 48 h. Specific measurement of total cerebellar GSH content at 24 h showed a decrease of about 85% with no increase in GSSG, indicating the absence of oxidative stress at that time . However, the GSH content, and hence antioxidant status in the cerebellum prior to the appearance of necrosis, is thus severely compromised, making the neuronal cells potentially more sensitive to glutamate toxicity (Murphy et al., 1989) . GSH exerts its antioxidant activity in synergy with ascorbate (Meister, 1995) and vitamin E. Vitamin E is essential for normal neurological function and is important as a free radical scavenger, while dehydroascorbate resulting from the oxidation of ascorbate is reduced by GSH (and NADPH) in the brain (Rose, 1993) . Interestingly, following L-2-CPA no reduction in cerebellar ascorbate or evidence of lipid peroxidation were observed, either prior to or at the time of cellular injury; however, calpain activation was seen suggesting proteolytic damage to the cytoskeleton (Widdowson et al., 1997) .
The decrease in hepatic GSH is due to direct conjugation with L-2-CPA to form 2-S-glutathionyl propanoic acid, the reaction being mediated by a GST present in the cytosolic fraction. HPLC analysis of the conjugates formed with D, L-2-CPA indicate the presence of two isomeric forms of the GSH conjugate, while with L-2-CPA only one isomer was formed, indicating no racemisation. Stereoselective conjugation of 2-bromocarboxylic acids and their urea derivatives with GSH by rat liver have been reported (Polhuijs et al., 1989) . The conjugation of 2-bromovaleric acid is catalyzed by a member of the theta class GSTs, also with a high degree of stereospecificity, with only the R-enantiomer being conjugated (Polhuijs et al., 1992) . Both L-2-CPA and D-2-CPA hepatic conjugation are mediated by a GST. Partial purification of this enzyme showed it did not bind to an S-hexylGSH affinity column, and therefore it was assumed to be a member of the theta class GSTs. The enzyme has a higher affinity for the L-isomer than the D-isomer of CPA . A new GST has recently been discovered and named zeta; this isoform also does not bind to an S-hexylGSH affinity column (Board et al, 1997) . Studies have shown that L-2-CPA (Anders and Tonge, 1998) and other 2-halopropionic acids are substrates for zeta GST and not theta GSTs (Sherratt and Lock, unpublished observation) .
No conjugation of L-2-CPA with GSH occurs in the presence of rat cerebellar or forebrain cytosol or whole brain homogenate. This finding is somewhat surprising as rat brain contains GST's Johnson et al., 1993) although it is not known if zeta GST is present. It is also possible that the analytical method is not sensitive enough to detect the presence of the conjugate or that insufficient time was allowed for the reaction to occur in vitro.
An alternative explanation for the reduction in cerebral GSH is that L-2-CPA or its cysteine conjugate could prevent cerebral GSH synthesis either by a direct inhibition of ␥-glutamyl cysteine synthetase or by reducing cysteine entry into the brain. The transport into the brain of cysteine as cystine is the rate-limiting step in the synthesis of GSH (Bannai and Tateishi, 1986) . It has been proposed that cystine is primarily taken up by glial cells, which then supply cysteine to neuronal cells to support GSH synthesis (Sagara et al., 1993;  Fig. 1 ). One consequence of lowering GSH content in neurons is that they become more susceptible to oxidative stress and glutamate toxicity (Murphy et al., 1989) . The L-2-CPA cysteine conjugate is a non-competitive inhibitor of cystine transport in slices of rat cerebellum with an apparent Ki of 60 M . Whether this is a contributing factor to the toxicity in vivo is currently not clear, but the cysteine conjugate of L-2-CPA is certainly present in the plasma at a concentration of about 100 M for an extended period of time after dosing.
An important subject for investigation is the role of GSH in the cerebellar neurotoxicity produced by L-2-CPA and related 2-halopropionic acids. Modulation of the GSH status of rats by inhibiting GSH synthesis with buthionine sulphoximine (Meister, 1991) followed by L-2-CPA markedly potentiates the neurotoxicity and in addition produces renal tubular necrosis . In contrast, administering GSH exogenously, as the isopropyl ester, protects rats from the cerebellar toxicity, supporting the view that GSH is neuroprotective. These findings are consistent with studies showing that parenteral administration (Lock, unpublished observation) or intracerebral injection (T. Monks, personal communication) of either the GSH or cysteine conjugate of L-2-CPA to rats does not cause cerebellar toxicity. Overall, these findings indicate that conjugation of L-2-CPA with GSH is a detoxication reaction.
Prior to the above studies, we considered the possibility that L-2-CPA or its GSH or cysteine conjugate might mimic glutamate, leading us to examine if the neurotoxicity was mediated through glutaminergic ionotropic receptors such as NMDA-gated channels (Garthwaite, 1994) . Excitotoxicity in the brain may occur when an endogenous or exogenous compound activates a glutamate receptor. Glutamate is quantitatively the most important neurotransmitter in the brain, and glutamate receptors are localized in most brain regions. Pharmacological studies using selective agonists and antagonists have identified 4 distinct classes of binding sites in mammalian brain, which are named according to the agonist: AMPA (␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), kainate, NMDA, and quisqualate-sensitive metabotropic sites (Dawson et al., 1995; Fonnum, 1997; Monaghan et al., 1989) . The NMDA receptor is particularly important in excitotoxicity. It is an ion channel that is permeable to Ca 2ϩ and Na ϩ influx, is gated by Mg 2ϩ , and requires glycine as a co-agonist for full receptor activation. The receptor can be blocked by NMDA antagonists, glycine site antagonists, or ion channel blockers such as MK-801 [(5R,10S)-(ϩ)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine].
Prior treatment of rats with relatively high doses of the irreversible NMDA receptor antagonist MK-801 (Wong et al., 1986) , followed 30 min later by L-2-CPA, prevents the clinical signs of neurotoxicity, changes in cerebellar morphology, and decreases in cerebellar neurotransmitter content (Widdowson et al., 1996c) . Subsequent studies have shown that 5 to10-fold lower doses of MK-801, followed 30 min later by L-2-CPA will also afford neuroprotection. Delaying the MK-801 until 1 h post-treatment also affords almost complete protection. However extending post-treatment to 2 or 6h after L-2-CPA gives only limited neuroprotection . This finding suggests that L-2-CPA neurotoxicity is the result of selective activation of cerebellar NMDA receptors leading to glutamate release, or that it may act via an indirect pathway resulting in glutamate release or retention in the extracellular space. These studies indicate L-2-CPA produces neuronal cell death by an excitotoxic mechanism.
Excitotoxicity is not due to a single event, but to a cascade of events, which is initiated by excessive extracellular exposure to an excitatory compound, such as glutamate or cysteine. There are two phases in the process, one fast and one slow. The fast phase is due to swelling caused by an increase of Na ϩ influx via the receptor, which leads to a further increase of water and Cl -influx. The slow phase is believed to be more important for neuronal cell death, where the increase in intercellular Na ϩ leads to depolarization of the neuron, with a consequent release of Mg 2ϩ from the NMDA receptor and a rise in intracellular Ca 2ϩ (Choi, 1992) . Elevation of intracellular Ca 2ϩ is a major event in excitotoxicity leading to activation of enzymes such as calpains, endonucleases, and phospholipase A 2 , resulting in cytoskeletal damage. The changes in [Ca 2ϩ ]i are buffered by Ca 2ϩ sequestration into mitochondria, and this Ca 2ϩ current induces depolarization of the inner mitochondrial membrane (Schinder et al.,1996) . This depolarization allows the release of ROS from the mitochondria, which, together with those generated by activation of NMDA receptors (Lafon-Cazal et al., 1993) and by the peroxynitrite formed by the Ca 2ϩ -dependant activation of nitric oxide synthase (Moncada et al., 1991) , are all thought to contribute to the cascade of events leading to neuronal cell death.
Treatment of rats with antagonists of the glutamate site on the NMDA receptor have also been shown to afford neuroprotection against L-2-CPA-induced cerebellar granule cell necrosis, while glycine site antagonists have no effect . Inhibition of NO synthase with agents such as N G -nitro-L-arginine methyl ester and 3-bromo-7-nitroindazole, which can cross the blood brain barrier, also affords partial
FIG. 1.
Overview of the neuronal-glial cell cysteine transport for GSH synthesis and possible sites for interaction by L-2-CPA: Because cysteine is the rate-limiting precursor for GSH synthesis, cellular GSH levels are affected by cysteine supply. In extracellular fluid, cysteine is rapidly oxidized to cystine, which is actively transported into glial cells. S-2-cysteinyl propanoic acid (L-2-PA-cysteine), a metabolite of L-2-CPA, inhibits cystine uptake and could potentially reduce both neuronal and glial cell GSH. Alternatively, glutathione S-transferase (GST) catalyzes conjugation of L-2-CPA with GSH and could occur in either cell type (see text). L-2-CPA may enter the brain via the propionic acid or lactic acid transporter.
protection against the selective cerebellar toxicity, further supporting an excitotoxic mechanism . These findings are consistent with the hypothesis that release of extracellular glutamate and production of peroxynitrite radicals in the cerebellum at a time when the anti-oxidant (GSH) status is compromised may predispose the granule cells to injury.
The basis for the selective vulnerability of the cerebellum to L-2-CPA may be due to the heterogeneity of NMDA receptors in different brain regions. Molecular biological studies have identified two families of NMDA receptor subunits (NR1 and NR2A-D) and these have been cloned and sequenced from rat. NR1 subunits can form functional homo-oligomeric receptors. However, co-expression of NR1 with NR2A, NR2B, or NR2C greatly enhances responses to NMDA (Buller et al., 1994 and reference therein) . Pharmacology and electrophysiology studies have also identified four pharmacologically distinct populations of NMDA receptors. Two of these are found in the cerebellum, which displays very distinct pharmacological profiles at both the glutamate and ion channel-blocking sites. Localization of NR2C m-RNA selectively to the cerebellum suggests that this unique cerebellar subtype is responsible for the distinct pharmacological properties. The selective toxicity of L-2-CPA may be due to this distinct cerebellar NMDA receptor. This notion is supported by binding studies showing that L-2-CPA and other 2-halopropionic acids displace [
3 H]-MK-801 binding from cerebellar but not forebrain membranes, suggesting they are weak agonists at the ion-channel site on cerebellar NMDA receptors (Lock et al., 1998) .
Recent studies with 2-fluoro-and 2-bromopropionic acids (2-FPA, 2-BPA) has shown that 2-FPA at molar equivalent doses to L-2-CPA produces no cerebellar injury, whereas 2-BPA does. Administration of 2-BPA, but not 2-FPA, also causes a marked depletion of hepatic and cerebellar GSH (Lock et al., 1998) , suggesting that a decrease in cerebellar GSH may be a prerequisite for the cellular injury. Both analogues can displace [ 3 H]-MK-801 from binding to rat cerebellar membranes in vitro, with the IC 50 for 2-FPA being very close to that seen with L-2-CPA. Taken together, these findings suggest that a combined activation of NMDA receptors, selectively expressed on cerebellar granule cells, and a marked and sustained depletion of cerebellar GSH, and hence antioxidant status, may predispose the granule cells to glutamate toxicity (Fig. 2) . Whether these 2-halopropionic acids interact directly with cerebellar NMDA receptors leading to glutamate release or whether glutamate is released by exocytosis as described for peroxynitrite and nitric oxide donors (Leist et al., 1997) remains to be established.
In this model of selective cerebellar neuronal cell death, GSH plays a pivotal neuroprotective role. It conjugates and removes the 2-halopropionic acid; however, at high doses the extent of cellular GSH depletion may be such that cells fall victim to L-2-CPA-mediated glutamate release, leading to excitotoxicity. In contrast to providing protection against chemical-induced toxicities, conjugation of certain chemicals with GSH may predispose cells and tissues to injury Lau, 1997, 1998) . Although GSH conjugates can cause toxicity by a variety of mechanisms, the important role played by cysteine conjugate ␤-lyase in many of these pathways is particularly well characterized.
Metabolism of Cysteine S-Conjugates in Brain: Role in Neurotoxicity
Trichloroethylene is an industrial solvent that is also a common pollutant of ground water (Roush, 1995) . This compound causes fatal aplastic anemia in cattle (Stockman, 1916) , and the cysteine S-conjugate [S-(1,2-dichlorovinyl)-L-cysteine (DCVC)] is responsible for this effect. (McKinney et al., 1959) . DCVC is also nephrotoxic to experimental animals, including cattle. . Exposure to trichloroethylene causes an increase in the incidence of renal tumors in laboratory animals (Dekant et al., 1990 Koob and Dekant, 1991) , and possibly in humans.
Trichloroethylene is detoxified in part by the mercapturate
The first step is an addition-elimination reaction catalyzed by microsomal GST. The next three steps are catalyzed by ␥-GT, cysteinylglycine dipeptidase, and an N-acetylase, respectively (Cooper, 1994; 1998b; Cooper and Tate, 1997; Dekant et al., 1994) . The mercapturate pathway serves to detoxify potentially harmful halogenated xenobiotics and to metabolize several endogenous compounds, such as leukotrienes and estrogens (Nicholson, 1993) . However, the pathway can also be involved
Proposed excitotoxic mechanism of L-2-CPA-induced cerebellar granule cell necrosis in the rat and the role of GSH as a neuroprotective agent: L-2-CPA may activate a specific subunit of NMDA receptors expressed on cerebellar granule cells, and could trigger the established cascade of events leading to neuronal cell death. Metabolism of L-2-CPA by conjugation with GSH leads to the formation of a non-toxic product and hence is a detoxication pathway. However, GSH depletion and perhaps a reduction in cysteine transport for GSH synthesis may make granule cells more susceptible to glutamate toxicity.
in bioactivation (toxication) reactions. In vivo, separate enzymes are involved in the acetylation and deacetylation of mercapturates, the formation of which is thus a reversible process. In contrast, a group of enzymes, known as cysteine S-conjugate ␤-lyases, irreversibly converts DCVC and similar cysteine S-conjugates to pyruvate, ammonia, and a reactive sulfur-containing fragment. The eliminated fragment is highly unstable, losing HCl to form a thioacetylating agent (probably a thioketene) . Some cysteine S-conjugates of halogenated alkanes are also nephrotoxic [e.g., S-(1,1,2,2-tetrafluoroethyl)-L-cysteine, TFEC]. In this case the eliminated fragment loses HF to form chlorofluorothioacetyl fluoride, which is also a thioacetylating agent . The ⑀-amino groups of protein lysines are vulnerable to attack by these thioacetylating agents.
Trichloroethylene is neurotoxic under certain circumstances. Human neurotoxicity associated with exposure to trichloroethylene (Buxton and Haywood, 1967) is probably due to contaminating dichloroacetylene (Greim et al., 1984; Reichert et al., 1967) . Dichloroacetylene, like trichloroethylene, is converted to DCVC in vivo. Dichloroacetylene, however, is a much better substrate of microsomal GST than is trichloroethylene; in fact, dichloroacetylene is the best-known substrate (Kanhai et al., 1989; Koob and Dekant, 1991) . This fact explains why dichloroacetylene is acutely nephrotoxic and neurotoxic whereas trichloroethylene is not (Kanhai et al., 1989) .
Mammalian cysteine S-conjugate ␤-lyases. Generally, these enzymes contain pyridoxal 5Ј-phosphate (PLP) and have well-defined metabolic functions. They are, however, "coerced" into catalyzing a ␤-elimination reaction when a good leaving group resides in the ␤ position of the substrate (Cooper 1998b) . Enzymes with strong cysteine S-conjugate ␤-lyase activity include kynureninase (Stevens et al., 1985) , cytosolic glutamine transaminase K (cytGTK), (Stevens et al., 1986) , kynurenine-pyruvate aminotransferase (Mosca et al. 1994 ) and a high M r of unknown function (Abraham et al., 1995a,b; Kim et al., 1997) . CytGTK and kynurenine aminotransferase have strong overlapping substrate specificities and show about 95% sequence homology (Abraham and Cooper, 1996) . PLP enzymes with weak cysteine S-conjugate ␤-lyase activity include alanine aminotransferase and the cytosolic and mitochondrial forms of aspartate aminotransferase (Kato et al., 1996) . Kynureninase (Stevens, 1985) , alanine aminotransferase, and cytosolic aspartate aminotransferase (Kato et al., 1996) are inactivated by the products of the lyase reaction, presumably due to attack of the aminoacrylate intermediate on a susceptible protein residue, or more likely, on the PLP cofactor itself (Ueno et al., 1982) . Possibly, part of the toxicity associated with certain cysteine S-conjugates lies in the inactivation of metabolically important PLP enzymes.
Neurotoxicity of cysteine s-conjugates.
Post-mortem study of an individual severely affected by trichloroethylene/dichloroacetylene poisoning showed neuronal degeneration within the brainstem sensory nucleus of the trigeminal nerve and degeneration of axons within its tract (Buxton and Hayward, 1967) . Similar damage occurs in animals exposed to dichloroacetylene (Reichert et al., 1976) . Little is known about the mechanism of neurotoxicity of dichloroacetylene/DCVC in the brain. However, both S-(1,2-dichlorovinyl) glutathione and DCVC are transported across the blood-brain barrier (Patel et al., 1993) . DCVC appears to be transported by the L carrier system (Patel et al., 1993) . Moreover, kynureninase, kynurenine-pyruvate aminotransferase (Alberati-Giani, 1995) , and GTK (Cooper et al., 1993) are present in rat brain. The specific activity of GTK is much higher in the choroid plexus than in whole brain (Cooper et al., 1993) . As noted above, GSTs are well represented in the brain. ␥-GT and some other enzymes of the ␥-glutamyl cycle are present in brain capillaries, neurons and astrocytes (Cooper, 1997) , and at high levels in the choroid plexus (Tate et al., 1973) . Immunohistochemical studies showed that microsomal GST is present in brain in cerebral cortical and cerebellar Purkinje cells and in nuclei within the choroid plexus (Otieno et al., 1997) . Patel et al. (1994) showed that brain homogenates could convert DCVC to pyruvate and to the corresponding ␣-keto acid. Previously, the high M r lyase was not detectable in whole homogenates of rat brain (Abraham et al., 1995b) , but recent work indicates that the enzyme is present in the choroid plexus (unpublished data).
Finally, administration of [ 35 S]-and [cysteine U-14 C]-labeled DCVC to rats led to accumulation of label in several tissues, including brain (Finkelstein et al., 1995) . Therefore, the necessary machinery is in place for accumulation of cysteine S-conjugates in the brain-either by metabolism of the halogenated xenobiotic directly within the brain or by uptake of the GSH-or cysteine S-conjugate across the blood-brain barrier/ choroid plexus. The necessary machinery is also present for the conversion of the conjugate to potentially toxic fragments within the brain, especially within the choroid plexus, although the exact mechanism of the ␤-lyase-mediated neurotoxicity of cysteine S-conjugates remains to be determined. In addition to the ␤-lyase mediated toxicity of GSH/cysteine conjugates, several para-diphenols (hydroquinones) and ortho-diphenols (catechols) are targeted to specific cells and tissues via conjugation with GSH Lau, 1997, 1998) , and may contribute to several neurodegenerative processes.
The Role of GSH in the Serotonergic Neurotoxicity of 3,4-(Ϯ)-Methylenedioxyamphetamine and 3,4-(Ϯ)-Methylenedioxymethamphetamine
3,4-(Ϯ)-Methylenedioxyamphetamine (MDA) and 3,4-(Ϯ)-methylenedioxymetamphetamine (MDMA; Ecstasy) are ringsubstituted amphetamine derivatives, structurally related to psychomotor stimulant amphetamines and the hallucinogen mescaline. Peripheral administration of MDA or MDMA causes decreases in markers of serotonergic function, including serotonin (5-hydroxytryptamine or 5-HT), and in the 5-HT carrier protein in serotonergic nerve terminal fields. These effects are of concern to the general population, because primates are especially susceptible to the toxicity of these agents, and the recreational use of MDMA is increasing in the United States and Europe (Commins et al., 1987; Ricaurte et al., 1985 Ricaurte et al., , 1988 . The neurotoxic component(s) of MDA and MDMA is (are) not known, but roles for endogenous dopamine, and for the 5-HT 2 receptor are proposed. When injected directly into the brain, MDA and MDMA are not neurotoxic, implying that systemic metabolism plays an important role in the development of neurotoxicity (Schmidt and Taylor, 1988) . The nature of the metabolite(s) responsible for MDA-and MDMA-mediated neurotoxicity is unclear. Therefore, because: (i) ␣-methyldopamine is a metabolite of MDA and MDMA (Lim and Foltz, 1988; Lin et al., 1992; Hiramatsu et al., 1990; Midha et al., 1978) ; (ii) and is readily oxidized to the ortho-quinone, followed by conjugation with GSH; (iii) the conjugation of quinones with GSH frequently results in preservation or enhancement of biological (re)activity Lau, 1997, 1998) ; and (iv) there appears to be a protein capable of transporting GSH from the circulation into the brain (Kannan et al., 1990) , a role of quinone-thioethers in the acute neurobehavioral and long-term neurochemical changes that occur after administration of MDA was proposed (Miller et al., 1995) .
Intracerebral metabolism of 5-(glutathion-S-yl)-␣-methyldopamine.
One such putative quinone-thioether metabolite of MDA, 5-(glutathion-S-yl) -␣-methyldopamine, is rapidly cleared from the brain and is metabolized via the mercapturic acid pathway to 5-(cystein-S-yl) -␣-methyldopamine (Miller et al., 1995) . Concentrations of the cysteine conjugate also decline rapidly, with the concomitant formation of 5-(N-acetyl-cystein-S-yl)-␣-methyldopamine which, in contrast to 5-(glutathion-S-yl)-methyldopamine and 5-(cystein-S-yl)-␣-methyldopamine, is eliminated relatively slowly from the brain (Miller et al., 1995) . 5-(Glutathion-S-yl)-␣-methyldopamine is also readily oxidized to the corresponding quinone-GSH conjugate and undergoes addition of a second molecule of GSH to form 2,5-bis-(glutathion-S-yl)-␣-methyldopamine.
Neurotoxicity of 5-(glutathion-S-yl)-␣-methyldopamine and its metabolites.
The potential neurotoxicity of 5-(glutathion-S-yl)-␣-methyldopamine and its major metabolites was subsequently determined (Miller et al., 1996 (Miller et al., , 1997 . A single icv injection of 5-(glutathion-S-yl)-␣-methyldopamine (720 nmol) to male Sprague-Dawley rats causes short-term changes in neurotransmitter levels similar to those seen after subcutaneous administration of MDA (20 mg/kg, 23 mol/rat) (Miller et al., 1996) . The behavioral changes seen after 5-(glutathion-S-yl)-␣-methyldopamine are also compatible with it contributing to the behavioral and/or neurotoxic effects of MDA and MDMA. However, although 5-(glutathion-S-yl)-␣-methyldopamine reproduces some of the effects of MDA on the dopaminergic system, and is capable of causing acute increases in serotonin (5-HT) turnover, it does not cause long-term serotonergic toxicity (Miller at al., 1996) .
Although multiple icv injections of 5-(glutathion-S-yl)-␣-methyldopamine (4 ϫ 720 nmol) and 5-(N-acetylcystein-S-yl)-␣-methyldopamine (4 ϫ 100 nmol) to Sprague-Dawley rats produce overt behavioral changes similar to those seen following administration of MDA (93 mol/kg; sc) (Miller at al., 1996) , they do not produce long-term decreases in brain 5-HT concentrations. In contrast, 2,5-bis-(glutathion-S-yl)-␣-methyldopamine (4 ϫ 475 nmol) decreases 5-HT levels in the striatum, hippocampus and cortex, 7 days after injection (Miller at al., 1997) . The relative sensitivity of the striatum, hippocampus, and cortex to 2,5-bis-(glutathion-S-yl)-␣-methyldopamine is the same as that observed for MDA, although the absolute effects are greater with MDA. The effects of 2,5-bis-(glutathion-S-yl)-␣-methyldopamine are also selective for serotonergic nerve terminal fields, in that 5-HT levels are unaffected in regions of the cell bodies (Miller at al., 1997) . Because 2,5-bis-(glutathion-S-yl)-␣-methyldopamine causes long term depletion in 5-HT without adversely affecting the dopaminergic system, it also mimics the selectivity of MDA/ MDMA. The data imply a role for quinone-thioethers in the neurobehavioral and neurotoxicological effects of MDA/ MDMA. Since polyphenolic thioethers maintain the ability to redox cycle , and because all the thiol conjugates of ␣-methyldopamine remain susceptible to oxidation, the presence and persistence of these metabolites in brain tissue may contribute to the neurotoxicity of MDA and MDMA. The unique bi-functional nature of quinone-thioethers facilitates their interaction with several enzymes that have quinones as their usual substrates and/or GSH as a cofactor (Monks and Lau, 1994) .
Transport of GSH and GSH conjugates across blood brain barriers.
The catechol-GSH metabolites of MDA and MDMA must be capable of crossing the BBB and the BCSFB in order to produce toxicity. Brain microvascular endothelial cells maintain tight junctions (see above) and possess a high density of mitochondria, which supply the high-energy requirements for the transport of water-soluble substances through the endothelial barrier via specific transporters. The directionality of ion transport across the BBB is achieved by a polarized distribution of ion-channels on the endothelial cell surfaces. Therefore, endothelial cells are polarized in a manner similar to other transport interfaces, such as renal epithelia, with the preferential localization of specific transport systems and receptors either on the luminal or the antiluminal side of vessel walls (Schlosshauer, 1993) . For amino acids, at least three different carrier systems have been identified within the BBB (Oldendorf and Szabo, 1976) , and a variety of neurotoxicants are transported into brain across the BBB via these amino acid carriers. The cysteine conjugate of dichloroacetylene, a potent nephrotoxicant (Jackson et al., 1971) and neurotoxicant (Reichert et al., 1976) , is also transported across the BBB by the Na ϩ -independent system L-transporter for neutral amino acids, while uptake of the corresponding GSH conjugate is mediated by an as yet unknown carrier system (Patel et al., 1993) . The saturable, carrier-mediated transport of GSH across the blood-brain barrier has also been reported (Kannan et al., 1990) . Thus, transport systems that can facilitate the uptake of GSH and cysteine conjugates of ␣-methyldopamine into the brain have been described. GSH and 5-(glutathion-S-yl)-␣-methyldopamine apparently use the same transporter, since GSH decreases 5-(glutathion-S-yl)-␣-methyldopamine uptake into brain (Miller et al., 1996) . Interestingly, pretreatment of rats with acivicin, which inhibits ␥-GT, significantly increases the uptake of 5-(glutathion-S-yl)-␣-methyldopamine into brain, presumably by preventing its clearance from blood via metabolism and increasing the fraction available for uptake via the GSH transporter (Miller et al., 1996) .
The role of glia in MDA neurotoxicity. Little is known about the effects of MDA and MDMA on glial cells (astrocytes, oligodendrocytes, and microglia). Glia provide physical and trophic support for neurons, and their response to local or remote tissue injury may either protect or potentiate the injury. For example, although it has been speculated that astrocytes impair axonal regeneration in mammalian brain (Berry et al., 1983) in vitro data suggest that astroglia support neuronal growth (Ferrara et al., 1988) by elaborating neurotrophic factors (Giulian, 1993) . In contrast, activated microglia release a variety of potentially cytotoxic and growth factors, including ROS, eicosanoids (Giulian, 1992; Giulian and Baker, 1986) , IL-1, GM-CSF and TNF␣ (Giulian et al., 1994) . IL-1 serves as a growth factor for astroglia (Giulian et al., 1994) and may promote neuronal growth and survival through astroglial release of NGF (Fagan and Gage, 1990) . GC-MCF is mitogenic for microglia and therefore serves in an autocrine manner (Giulian et al., 1994) . Thus, the balance between the opposing actions of astroglia and microglia will determine the outcome of the glial response to chemical-induced injury. The glial response to MDA was therefore examined in vivo and in vitro. Rats were treated with MDA (20 mg/kg; sc) followed by biopsy culture to determine the activation of quiescent microglia, via endocytosis of acetylated low-density lipoprotein linked to 1,1Ј-dioctadecyl-1,3,3,3Ј,3Ј-tetramethyl-indocarbocyanine perchlorate, a fluorescent probe. A reactive microglial response was observed within 6 h of MDA administration, which reached a plateau by 72 h and had subsided by 7 days (Li et al., unpublished data) . The intensity of the microglial response in different regions of the brain varied in the following order: hippocampus Ͼ cortex Ͼ cerebellum Ͼ striatum Ͼ hypothalumus. Direct injection of MDA into the brain did not produce neurotoxicity nor did it produce a microglial response (Li et al., 1998) , implying a role for systemic metabolism in these effects. The effects of MDA and 5-(glutathion-S-yl)-␣-methyldopamine on primary cultures of E18 hippocampal mixed glial and neuronal cells were therefore compared. MDA (500 M) and 5-(glutathion-S-yl)-␣-methyldopamine (100 M) stimulated the proliferation of glial fibrillary acidic protein-positive astrocytes, increased the caliber of 5-HT axons, and induced the formation of large varicoses (Li et al., 1998) . The data indicate that glial cells play an important role in response to MDA and support a role for thioether metabolites of ␣-methyldopamine in MDA-mediated neurotoxicity
CONCLUSIONS AND FUTURE DIRECTIONS
Blood-brain interfaces regulate the cerebral disposition of a variety of potentially toxic chemicals, including blood-borne GSH and cysteine conjugates that may contribute to druginduced neurotoxicity. Blood-brain interfaces also participate in the cerebral disposition of metabolites formed directly in the brain. In several instances, transport proteins located at the BBB and/or the BCSFB contribute to these processes. The characterization of these proteins, especially those involved in the transport of GSH at the molecular level, and the elucidation of the underlying transport mechanisms may lead to new therapeutic strategies for the prevention and treatment of neuropharmacological and neurotoxicological side effects. The ability of blood-brain interfaces, and mainly the choroid plexuses, to metabolize toxicants is an emerging field of research that requires further investigation, both in terms of its contribution to brain protection mechanisms and of its ability to synthesize reactive metabolites. The role of the CSF in transporting toxicants to distant cellular targets also needs to be assessed.
The ability of GSH to protect against, and in some instances to mediate, the toxicity of chemicals is well established. The role of GSH in modulating the toxicity of chemicals that gain access to the brain is further complicated by recent findings of additional roles for GSH in brain function (reviewed in Shaw, 1998) . For example, GSH binding sites have been identified within the mammalian CNS (Ogita et al., 1988) suggesting a role for GSH as a neuromodulator or neurotransmitter. Consistent with this view, both GSH and its disulfide form (GSSG) modulate the NMDA receptor (Leslie et al., 1992) , and GSH also modulates -opioid, substance P/neurokinin-1, and kainic acid receptor binding (Liu and Quirion, 1992) . GSH and GSSG also elicit a potent antinociceptive activity (Kubo et al., 1992) . The finding that GSH produces an increase in second messenger synthesis (inositol 1,4,5-trisphosphate) in rat astrocytes (Guo et al., 1992) is also compatible with a role in receptormediated events. In rat brain slices, depolarization induces GSH secretion into the extracellular space in a Ca 2ϩ -dependent manner (Zangerle et al., 1990) . GSH may also be required to maintain the uptake of catecholamines into synaptosomes (Pileblad, et al 1989) , and it accelerates sodium channel inactivation in excised rat axonal membranes (Strupp, et al., 1992) . GSH is also important for maintaining the cellular thiol:disulfide balance, and several important enzymes and transporters involved in neurotransmitter synthesis and reuptake require the maintenance of reduced thiols for activity. These additional roles of GSH within the CNS, and no doubt those that remain to be discovered, provide a pharmacological basis coupling alterations in GSH homeostasis to the development of certain neurodegenerative processes. Thus, chemical-induced changes in brain GSH concentrations may have profound consequences. The challenge will be to distinguish between the direct effects caused by chemical exposure and the secondary effects arising from changes in GSH concentrations. The combination of the direct and secondary effects will determine the regional and cell type-specific responses to chemical exposure.
The direct neurotoxicity of certain GSH conjugates is an area for concern. For example, although Parkinson's disease is classically characterized by the loss of nigrostriatal dopaminergic neurons and decreases in concentrations of the neurotransmitter dopamine, the substantia nigra of Parkinson's patients also exhibits substantial decreases in the concentration of GSH, with a corresponding increase in the levels of 5-(cystein-S-yl)dopamine relative to dopamine. The addition of cysteine to either dopamine or 3,4-dihydroxyphenylalanine results in the formation of products that are more readily oxidized than the parent catechols (Shen and Dryhurst, 1996) and which may play a role in Parkinson's disease (Shen et al., 1997) . Indeed, the potent redox properties of these endotoxicants is consistent with the involvement of oxidative stress in the pathogenesis of Parkinson's disease. A defect in the metabolism 5-HT has also been implicated in various neurodegenerative, neuropsychiatric, and behavioral disorders (Wooley and Shaw, 1954) and serotonergic abnormalities occur in mental disturbances of the Alzheimer type (Palmer et al., 1987) . 5-HT is converted to several potent neurotoxic polyhydroxylated metabolites (Baumgarten et al., 1971 (Baumgarten et al., , 1972 and the CSF of Alzheimer's patients contains a product with properties consistent with tryptamine-4,5-dione (Matson et al., 1984) ). Since tryptamine-4,5-dione causes the release of 5-HT from serotonergic neurons (Chen et al., 1989) , it might also exhibit neurodegenerative properties. However, tryptamine-4,5-dione reacts rapidly with GSH to form several GSH conjugates which likely contribute to its neurodegenerative effects. Susceptibility of polyphenolic-GSH conjugates to further oxidation, and the reactivity of the resultant quinone-thioethers toward sulfhydryl groups is consistent with the proposition that endogenous quinone-thioethers contribute to the neurotoxicity of polyphenolic metabolites of 5-HT and dopamine. A comprehensive understanding of the disposition of these novel metabolites, and a determination of their pharmacological and toxicological properties, will enhance our understanding of their role in neurodegeneration.
